The Lesser of 2 Evils: The Ethics of Placebo-Controlled Trials

Rothman KJ Michels KB . The continuing unethical use of placebo controls. NEJM. 1994;331:394–398.

Khan A Khan S Brown WA . Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol. 2002;5:193–197.

Joffe R Sokolov S Streiner DL . Antidepressant treatment of depression: A meta-analysis. Can J Psychiatry. 1996;41:613–616.

Ogundipe LO Boardman AP Masterson A. Randomisation in clinical trials. Br J Psychiatry. 1999;175:581–584.

Chalmers TC Celano P Sacks HS , Bias in treatment assignment in controlled clinical trials. NEJM. 1983;309:1358–1361.

Heres S Davis J Maino K , Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185–194.

Margraf J Ehlers A Roth WT , How “blind” are double-blind studies? J Consult Clin Psychol. 1991;59:184–187.

Kemmler G Hummer M Widschwendter C , Dropout rates in placebo-controlled and active-controlled clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry. 2005;62:1305–1312.

Chan AW Hróbjartsson A Haahr MT , Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA. 2004;291:2457–2465.

Kim MY Goldberg JD . The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Stat Med. 2001;20:2065–2078.

Streiner DL . Unicorns do exist: A tutorial on “proving” the null hypothesis. Can J Psychiatry. 2003;48:756–761.